Marker-free plasmids for biotechnological applications – implications and perspectives - Inria - Institut national de recherche en sciences et technologies du numérique Accéder directement au contenu
Article Dans Une Revue Trends in Biotechnology Année : 2013

Marker-free plasmids for biotechnological applications – implications and perspectives

Résumé

Nonviral gene therapy and DNA vaccines have become the first promising approaches to treat, cure, or ultimately prevent disease by providing genetic information encoded on a plasmid. Since 1989, more than 1800 clinical trials have been approved worldwide, and approximately 20% of them are using plasmid DNA (pDNA) as a vector system. Although much safer than viral approaches, DNA vectors generally do encode antibiotic resistance genes in the plasmid backbone. These antibiotic resistance markers constitute a possible safety risk, and they are associated with structural plasmid instabilities and decreased gene delivery efficiency. These drawbacks have initiated the development of various antibiotic marker-free selection approaches. We provide an overview on the potential implications of marker-free plasmids and perspectives for their successful biotechnological use in the future.

Dates et versions

hal-04328020 , version 1 (06-12-2023)

Identifiants

Citer

Pedro Oliveira, Juergen Mairhofer. Marker-free plasmids for biotechnological applications – implications and perspectives. Trends in Biotechnology, 2013, 31 (9), pp.539-547. ⟨10.1016/j.tibtech.2013.06.001⟩. ⟨hal-04328020⟩
18 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More